Fibrocell Science is an autologous cell therapy company focused on the development of innovative products for medical, aesthetic, and scientific applications. The company is trying to advance the scientific, medical, and commercial potential of autologous skin and tissue as well as its innovative cellular processing and manufacturing technology.
The company is working in a research collaboration with the University of California, Los Angeles, on the conversion of dermal fibroblasts into pure functional human cell types that may have greater regenerative capacity. This research will set the stage for future diagnostics and treatments based on each individual’s cells for diseases such as Parkinson’s, diabetes, and heart disease.
Fibrocell announced today promising results from a study demonstrating a potential mechanism for converting research-grade adult skin cells into clinical-grade induced pluripotent (iPS) stem cells. The study was conducted under the lead of James Bryne, Ph.D. assistant professor at the UCLA Department of Molecular and Medical Pharmacology, at the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research.
The study provided proof of concept for this reprogramming method of converting adult skin cells to iPS cells. But it also confirmed that scientists can remove unwanted non-human contaminants from stem cell populations. The iPS cells produced during the study had the ability to transform into other critical cell types such as those of the brain, liver, and heart.
Using skin cells is usually easier on the patients since a skin biopsy is minimally invasive, less painful, and less time-consuming than obtaining cells from bone marrow or fat tissue. This programming approach developed by Fibrocell and UCLA may be used by researchers to evaluate new drug compounds for safety and to develop patient-specific therapies for a number of diseases.
For additional information about Fibrocell Science and this latest research study, please visit www.fibrocellscience.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website
http://www.missionir.com/disclaimer.html
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment